Skip to main content

Zinbryta FDA Approval History

Last updated by Judith Stewart, BPharm on April 7, 2021.

FDA Approved: Yes (Discontinued) (First approved May 27, 2016)
Brand name: Zinbryta
Generic name: daclizumab
Dosage form: Injection
Company: Biogen Inc.
Treatment for: Multiple Sclerosis

Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).

In March 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for the treatment of relapsing multiple sclerosis.

Development timeline for Zinbryta

Mar  2, 2018Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for Zinbryta (daclizumab) for Relapsing Multiple Sclerosis
May 28, 2016Approval FDA Approves Zinbryta (daclizumab) to Treat Multiple Sclerosis
Apr 29, 2015FDA Accepts BLA for Zinbryta (Daclizumab High-Yield Process) for Treatment of MS

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.